Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CTSS | P25774 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | BMP1 | P13497 | 3/20 | 0.38 |
| ▸ | MMP2 | P08253 | 2/20 | 0.38 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5403076 | 1.00 | PPARG (0.41) | PPARGMEN1GAAKMT2ACTSS | |
| SCHEMBL5415572 | 0.99 | PPARG (0.40) | PPARGMEN1GAAKMT2ACTSS | |
| SCHEMBL5415566 | 0.99 | PPARG (0.40) | PPARGMEN1GAAKMT2ACTSS | |
| Cyclohexylamine SCHEMBL5408520 | 0.94 | PPARG (0.38) | PPARGMEN1GAAKMT2ACTSS | |
| Cyclohexylamine SCHEMBL5408527 | 0.94 | PPARG (0.38) | PPARGMEN1GAAKMT2ACTSS | |
| SCHEMBL6872894 | 0.87 | BMP1 (0.37) | MEN1KMT2ACTSSCTSKBMP1 | |
| SCHEMBL5415569 | 0.86 | SMN1; SMN2 (0.36) | PPARGCTSSCTSKBMP1MMP2 | |
| SCHEMBL1704461 | 0.85 | CTSK (0.45) | PPARGMEN1GAAKMT2ACTSS | |
| SCHEMBL1914687 | 0.85 | CTSK (0.45) | PPARGMEN1GAAKMT2ACTSS | |
| SCHEMBL4985951 | 0.84 | PPARG (0.36) | PPARGMEN1GAAKMT2ACTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030119807-A1 | 3-Heterocyclylpropanohydroxamic acids | BAILEY SIMON (US) | 2003-06-26 | — | — | US | claimed |
| JP-2003519133-A | — | — | 2003-06-17 | — | — | JP | claimed |
| EP-1240152-A1 | OX(ADI)AZOLYL-HYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS | Pfizer Limited (GB) | 2002-09-18 | — | — | EP | claimed |
| US-20010021718-A1 | Procollagen C-proteinase inhibitors | PFIZER INC. | 2001-09-13 | — | — | US | claimed |
| WO-2001047901-A1 | OX(ADI)AZOLYL-HYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS | PFIZER LIMITED (GB) | 2001-07-05 | — | — | WO | claimed |
| US-7214694-B2 | 3-ox(adi)azolylpropanohydroxamic acids useful as procollagen C-proteinase inhibitors | PFIZER INC (US) | 2007-05-08 | — | — | US | disclosed |
| US-7214694-B2 | 3-ox(adi)azolylpropanohydroxamic acids useful as procollagen C-proteinase inhibitors | PFIZER INC (US) | 2007-05-08 | — | — | US | disclosed |
| US-7214694-B2 | 3-ox(adi)azolylpropanohydroxamic acids useful as procollagen C-proteinase inhibitors | PFIZER INC (US) | 2007-05-08 | — | — | US | disclosed |
| EP-1343771-B1 | 3-OX(ADI)AZOLYLPROPANOHYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS | PFIZER LTD (GB) | 2006-04-12 | — | — | EP | disclosed |
| EP-1373231-B1 | 3-HETEROCYCLYL-PROPANO-HYDROXAMIC ACID AS PCP INHIBITORS | PFIZER LTD (GB) | 2005-06-08 | — | — | EP | disclosed |
| US-6897306-B2 | 3-heterocyclylpropanohydroxamic acids | PFIZER PRODUCTS, INC. (US) | 2005-05-24 | — | — | US | disclosed |
| EP-1373264-B1 | 3-HETEROCYCLYLPROPANOHYDROXAMIC ACID AS PROCOLLAGEN C-PROTEINASE INHIBITORS | PFIZER LTD (GB) | 2004-12-22 | — | — | EP | disclosed |
| WO-2002079200-A1 | 3-HETEROCYCLYLPROPANOHYDROXAMIC ACID AS PROCOLLAGEN C-PROTEINASE INHIBITORS | PFIZER LIMITED (GB) | 2002-10-10 | — | — | WO | disclosed |
| EP-1240152-A1 | OX(ADI)AZOLYL-HYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS | Pfizer Limited (GB) | 2002-09-18 | — | — | EP | disclosed |
| US-6452041-B1 | REACTING ALDEHYDE OF FORMULA RCHO, OR A PROTECTED DERIVATIVE THEREOF SUCH AS A HEMIACETAL OR ADDUCT THEREOF SUCH AS A BISULPHITE, WITH A PHOSPHORUS COMPOUND TO OBTAIN SUCCINATE OR ITACONATE DERIVATIVE | PFIZER INC. | 2002-09-17 | — | — | US | disclosed |
| US-6448278-B2 | ANTISCARRING AGENT | PFIZER INC. | 2002-09-10 | — | — | US | disclosed |
| WO-2002050046-A1 | 3-OX(ADI)AZOLYLPROPANOHYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS | PFIZER LIMITED (GB) | 2002-06-27 | — | — | WO | disclosed |
| US-20020058832-A1 | Novel olefination process to itaconate and succinate derivatives | PFIZER INC. | 2002-05-16 | — | — | US | disclosed |
| US-20010021718-A1 | Procollagen C-proteinase inhibitors | PFIZER INC. | 2001-09-13 | — | — | US | disclosed |
| WO-2001047901-A1 | OX(ADI)AZOLYL-HYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS | PFIZER LIMITED (GB) | 2001-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010021718-A1 | Procollagen C-proteinase inhibitors | MMP1, CTSL, PREP | PPARG 1715/4885MEN1 2045/4885GAA 1264/4885 |
| US-20020058832-A1 | Novel olefination process to itaconate and succinate derivatives | HOGA1, HADHA, OGDH | PPARG 960/4885MEN1 3506/4885GAA 1848/4885 |
| US-20030119807-A1 | 3-Heterocyclylpropanohydroxamic acids | CPA1, MMP1, PREP | PPARG 842/4885MEN1 2545/4885GAA 887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.